These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10145140)

  • 41. Cost of breast cancer treatment. A 4-year longitudinal study.
    Legorreta AP; Brooks RJ; Leibowitz AN; Solin LJ
    Arch Intern Med; 1996 Oct; 156(19):2197-201. PubMed ID: 8885818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Effectiveness Analysis of Breast Cancer Screening in Rural Iran.
    Zehtab N; Jafari M; Barooni M; Nakhaee N; Goudarzi R; Larry Zadeh MH
    Asian Pac J Cancer Prev; 2016; 17(2):609-14. PubMed ID: 26925651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective cost-effectiveness analysis of screening mammography.
    Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
    J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammography screening for breast cancer.
    King JM
    Cancer; 1994 Apr; 73(7):2003-6. PubMed ID: 8137231
    [No Abstract]   [Full Text] [Related]  

  • 45. Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London.
    Bryan S; Brown J; Warren R
    J Epidemiol Community Health; 1995 Feb; 49(1):70-8. PubMed ID: 7707010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost evaluation of breast cancer screening in France.
    Lamarque JL; Pujol J; Cherifcheikh J; Laurent JC; Taourel P; Boulet P; Daurès JP; Séguret F; Guizard AV; Delande G; Negre M
    Acad Radiol; 1998 Sep; 5 Suppl 2():S336-9. PubMed ID: 9750847
    [No Abstract]   [Full Text] [Related]  

  • 47. [Mammography screening. Senselessly squandered money?].
    Rautenstrauch J
    MMW Fortschr Med; 2000 Mar; 142(12):4-8. PubMed ID: 10804710
    [No Abstract]   [Full Text] [Related]  

  • 48. Total cost-effectiveness of mammography screening strategies.
    Mittmann N; Stout NK; Lee P; Tosteson AN; Trentham-Dietz A; Alagoz O; Yaffe MJ
    Health Rep; 2015 Dec; 26(12):16-25. PubMed ID: 26676235
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population-based mammography screening results in substantial savings in treatment costs for fatal breast cancer.
    Kauhava L; Immonen-Räihä P; Parvinen I; Holli K; Kronqvist P; Pylkkänen L; Helenius H; Kaljonen A; Räsänen O; Klemi PJ
    Breast Cancer Res Treat; 2006 Jul; 98(2):143-50. PubMed ID: 16538536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dutch digital breast cancer screening: implications for breast cancer care.
    Timmers JM; den Heeten GJ; Adang EM; Otten JD; Verbeek AL; Broeders MJ
    Eur J Public Health; 2012 Dec; 22(6):925-9. PubMed ID: 22158996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic savings and costs of periodic mammographic screening in the workplace.
    Griffiths RI; McGrath MM; Vogel VG
    Oncology (Williston Park); 1996 Mar; 10(3):285-9; discussion: 289-94. PubMed ID: 8820444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The National Cancer Screening Program for breast cancer in the Republic of Korea: is it cost-effective?
    Kang MH; Park EC; Choi KS; Suh M; Jun JK; Cho E
    Asian Pac J Cancer Prev; 2013; 14(3):2059-65. PubMed ID: 23679319
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer screening in a private women's clinic.
    Tifft JG; Jarjoura D
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 1):1402-7. PubMed ID: 3381864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package.
    Kattlove H; Liberati A; Keeler E; Brook RH
    JAMA; 1995 Jan; 273(2):142-8. PubMed ID: 7799495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening mammography in women aged 40-49 years: analysis of cost-effectiveness.
    Rosenquist CJ; Lindfors KK
    Radiology; 1994 Jun; 191(3):647-50. PubMed ID: 8184041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
    Tina Shih YC; Dong W; Xu Y; Shen Y
    Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and cost-effectiveness of double reading in digital mammography screening: A systematic review and meta-analysis.
    Posso M; Puig T; Carles M; Rué M; Canelo-Aybar C; Bonfill X
    Eur J Radiol; 2017 Nov; 96():40-49. PubMed ID: 29103474
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk assessment, screening and prevention of breast cancer: A look at cost-effectiveness.
    Lebovic GS; Hollingsworth A; Feig SA
    Breast; 2010 Aug; 19(4):260-7. PubMed ID: 20399656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.